The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting edge data to practising healthcare professionals. Our aim is to provide clinically relevant information in order to enhance the caregivers' ability to provide optimal care for their gastrointestinal (GI) cancer patients. We will offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, will function as a hub of information for healthcare professionals.
Our initial focus for Advances in Gastrointestinal Cancer will centre on gastric cancer, with future expansion to all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
Breaking news from ESMO 2016 Congress, Copenhagen, Denmark
ESMO 2016 Congress highlights
- When is the optimal time for surgery following CRT for locally advanced rectal cancer? Results of the UK 6 vs...
- Gastroesophageal cancer surgery in high volume centres is associated with less postoperative mortality regardless of co-morbidity status Centralisation of surgery...
Article of the month
Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced or recurrent gastric cancer (JFMC45-1102)
Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al.
Int J Cancer 2016 Aug 13. [Epub ahead of print]
Selected and commented by Professor David Cunningham:
In this study, Japanese investigators examined the efficacy of 2nd line trastuzumab plus paclitaxel in gastric cancer patients with HER2 positive tumours. Of note, although patients had received prior chemotherapy, they were trastuzumab naïve. The objective radiological response rate was 37% and progression free and overall survival in this trial were survival were 5.1 (95% CI 3.8–6.5) and 17.1 (95% CI 13.5–18.6) months, respectively. These results are encouraging but there are several important caveats which must be considered...
Oxaliplatin-Induced Hepatoportal Sclerosis, Portal Hypertension, and Variceal Bleeding Successfully Treated With Transjugular Intrahepatic Portosystemic Shunt
Taoreed O. Lawal, Alton B. Farris, Bassel F. El-Rayes, Ram M. Subramanian, Hyun S. Kim
Clinical Colorectal Cancer
Posterior Reversible Encephalopathy Syndrome (PRES) After Treatment With Oxaliplatin and 5-Fluorouracil
Nicholas Truman, Daniel Nethercott
Clinical Colorectal Cancer, Volume 12, Issue 1, March 2013, Pages 70 - 72
Jane E. Rogers, Aki Ohinata, Arvind Dasari, Cathy Eng
Clinical Colorectal Cancer, Volume 13, Issue 1, March 2014, Pages e1 - e4
Reversible Posterior Leukoencephalopathy Syndrome During Regorafenib Treatment: A Case Report and Literature Review of Reversible Posterior Leukoencephalopathy Syndrome Associated With Multikinase Inhibitors
Zaw W. Myint, Jeremy M. Sen, Nicole L. Watts, Thomas J. Druzgal, Barnett R. Nathan, Melanie D. Ward, James E. Boyer, Paula M. Fracasso
Clinical Colorectal Cancer, Volume 13, Issue 2, June 2014, Pages 127 - 130
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil–Induced Cardiac Vasospasm
Craig A. Vargo, Marlo Blazer, Joshua Reardon, Martha Gulati, Tanios Bekaii-Saab
Clinical Colorectal Cancer, Volume 15, Issue 2, June 2016, Pages e61 - e63
Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research
- Dec 201611Dec 201613
Congress CareRAI AmsterdamAmsterdam, Netherlands
- Dec 201616Dec 201619
ESMOSuntec Singapore Convention & Exhibition CentreSingapore, Singapore